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Background
In two Phase III randomized trials in MM, Ipi improved
median overall survival (OS) [1,2]. Here, we evaluate OS
and characterize post-Ipi treatment patterns among
long-term survivors from a single-institution cohort of
patients (pts) treated with Ipi.
Methods
Through a search of institutional databases, we identified
766 pts with MM treated with Ipi between 1/1/2003 and
12/31/2013. As of 4/1/2014, 96 pts have survived ≥2 yrs,
measured from first dose of Ipi. OS was calculated utiliz-
ing the Kaplan-Meier method. Disease control was defined
as the duration from initiation of Tx until initiation of
subsequent systemic Tx or death.
Results
With a median follow-up of 17mo (range 0-9yr), the med-
ian OS for the entire cohort of 766 pts was 15mo, with a
2-yr OS of 41%. Of the 80 pts with OS ≥2 yrs post-Ipi for
whom data are available, 75% (n = 60/80) remain alive and
30% (n = 24/80) remain progression-free following Ipi,
with median Ipi disease control of 15mo (range: 3 to 107
+mo). Among pts with progression (n = 56), 57% exhibited
disseminated progression, 29% oligometastatic progres-
sion, and 15% CNS-only progression. The most frequent
Tx at first progression was locoregional (n = 29),
employed at a median of 11mo post-Ipi (range: 3 to 55mo)
and associated with median 15+mos disease control
(range 1 to 73+mo) (table 1). In pts requiring post-Ipi
systemic Tx, long-term disease control was observed
across multiple systemic Tx’s (table 2).
Conclusion
Within this single-institution cohort, the median OS and
2-yr OS were greater than reported previously in Phase III
trials [1,2]. Potential reasons for this survival advantage
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Table 1 Pts receiving locoregional Tx at first progression.
Locoregional Tx # pts # pts achieving ≥1yr
disease control
CNS, surgery and/or RT 9/80 (11%) 5/9 (56%)
Non-CNS, surgery 11/80 (14%) 8/11 (73%)
Non-CNS, RT 6/80 (8%) 3/6 (50%)
Ablation 2/80 (3%) 1/2 (50%)
Table 2 Post-Ipi Systemic Txs.
Post-Ipi
Systemic Tx





















*pts with ongoing disease control and <1yr follow up excluded
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include: referral bias, heterogeneous Ipi dosing/schedule,
and access to subsequent trials (i.e. anti-PD-1/PD-L1,
BRAF inhibitor). The majority of long-term survivors
required subsequent Tx, however prolonged disease
control was achieved with a range of Tx’s. Pts who experi-
ence oligometastatic/CNS-only progression following Ipi
may achieve prolonged disease control with locoregional
Tx alone.
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